{
    "ticker": "AMPX",
    "name": "Ampio Pharmaceuticals, Inc.",
    "description": "Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for various medical conditions. Founded in 2010 and headquartered in Englewood, Colorado, Ampio specializes in the development of treatments that address unmet medical needs, particularly in the areas of inflammation and regenerative medicine. The company is primarily known for its lead product candidate, Ampion, which is currently being evaluated for its efficacy in treating osteoarthritis of the knee and other inflammatory conditions. Ampio's proprietary technology utilizes a novel formulation of human serum albumin, which has shown potential in reducing pain and improving function in patients suffering from degenerative diseases. The company's mission is to enhance patient outcomes through the development of safe and effective therapies that improve quality of life. Ampio is committed to leveraging its innovative technologies and clinical research to bring new treatments to market, aiming to make a significant impact in the biopharmaceutical landscape. With a robust pipeline and strategic partnerships, Ampio Pharmaceuticals continues to advance its research and development efforts, striving to deliver breakthrough therapies that address the challenges faced by patients and healthcare providers.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Englewood, Colorado, USA",
    "founded": "2010",
    "website": "https://www.ampiopharma.com",
    "ceo": "Michael Macaluso",
    "social_media": {
        "twitter": "https://twitter.com/ampiopharma",
        "linkedin": "https://www.linkedin.com/company/ampio-pharmaceuticals/"
    },
    "investor_relations": "https://ir.ampiopharma.com",
    "key_executives": [
        {
            "name": "Michael Macaluso",
            "position": "CEO"
        },
        {
            "name": "Dr. John M. W. W. H. B. Lee",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Ampion"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ampio Pharmaceuticals, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Learn about Ampio Pharmaceuticals, Inc., a leader in developing innovative therapies for inflammatory conditions. Explore our pipeline and commitment to patient care.",
        "keywords": [
            "Ampio Pharmaceuticals",
            "Ampion",
            "Biopharmaceuticals",
            "Inflammation",
            "Regenerative Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Ampio Pharmaceuticals known for?",
            "answer": "Ampio Pharmaceuticals is known for its innovative biopharmaceutical therapies, particularly its lead product candidate, Ampion."
        },
        {
            "question": "Who is the CEO of Ampio Pharmaceuticals?",
            "answer": "Michael Macaluso is the CEO of Ampio Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Ampio Pharmaceuticals headquartered?",
            "answer": "Ampio Pharmaceuticals is headquartered in Englewood, Colorado, USA."
        },
        {
            "question": "What is Ampion used for?",
            "answer": "Ampion is being evaluated for its efficacy in treating osteoarthritis of the knee and other inflammatory conditions."
        },
        {
            "question": "When was Ampio Pharmaceuticals founded?",
            "answer": "Ampio Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY"
    ],
    "related_stocks": [
        "NVS",
        "PFE",
        "GILD",
        "ABBV"
    ]
}